HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Gout With Hyperuricemia in Adults

Conditions

Gout With Hyperuricemia in Adults

Trial Timeline

Jun 1, 2024 → Jun 1, 2026

NCT ID

NCT06414837

About HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets

HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Gout With Hyperuricemia in Adults. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06414837. Target conditions include Gout With Hyperuricemia in Adults.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06414837	Phase 3	Recruiting	Jun 1, 2024	Jun 1, 2026	Gout With Hyperuricemia in Adults
NCT06139393	Phase 3	Completed	Dec 14, 2023	Sep 4, 2025	Gout With Hyperuricemia in Adults
NCT05347498	Phase 1	UNKNOWN	Apr 30, 2022	Jul 31, 2022	Primary Gout With Hyperuricemia in Adults

Competing Products

20 competing products in Gout With Hyperuricemia in Adults

See all competitors

Product	Company	Stage	Hype Score
febuxostat + Allopurinol	Astellas Pharma	Phase 3	77
Dotinurad + Febuxostat	Eisai	Phase 3	77
Baricitinib	Eli Lilly	Phase 2	52
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets	Jiangsu Hengrui Medicine	Phase 1	33
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tablet	Jiangsu Hengrui Medicine	Phase 2	52
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placebo	Jiangsu Hengrui Medicine	Phase 1	33
SHR4640 + placebo	Jiangsu Hengrui Medicine	Phase 1	33
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MG	Jiangsu Hengrui Medicine	Phase 3	77
Colchicine + Febuxostat + SHR4640	Jiangsu Hengrui Medicine	Phase 1	33
SHR4640 + Allopurinol	Jiangsu Hengrui Medicine	Phase 3	77
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + Febuxostat	Jiangsu Hengrui Medicine	Phase 2	52
SHR4640	Jiangsu Hengrui Medicine	Phase 1	33
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets	Jiangsu Hengrui Medicine	Phase 3	77
SHR4640 + Placebo	Jiangsu Hengrui Medicine	Phase 1	33
Zurampic® + Control group: xanthine oxidase inhibitor monotherapy	AstraZeneca	Pre-clinical	23
Risk of selected safety events	AstraZeneca	Pre-clinical	23
AZD6140 + Placebo to match AZD6140	AstraZeneca	Phase 1	33
RDEA3170 + Allopurinol + Placebo	AstraZeneca	Phase 2	52
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	41
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo	Novartis	Phase 3	77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved